According to him, the analysis of the data of the second and third phases of clinical trials, the data of the first month of hospital use of the drug suggests that it shows "the best results when used at the very beginning of the disease and at the middle stage of the disease", RIA Novosti reports.
“In this regard, we turned to the Ministry of Health with a request to allow the use of Avifavir on an outpatient basis by those patients who suffer from coronavirus infection at home,” he said.
On May 30, an anti-COVID-19 drug called Avifavir received approval from the Ministry of Health.
The RDIF stated that the drug will be free in Russia as part of the compulsory medical insurance.